Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2019-02-20
Target enrollment:
Participant gender:
Summary
This is an open label Phase II/III study to evaluate the efficacy and safety of test drug,
Insulin Tregopil (IN-105) compared with Insulin Aspart (IAsp) in Type 2 Diabetes Mellitus
patients. on stable dose of Metformin and insulin Glargine. The study will be conducted in 2
parts, Part I and Part II. The study duration will be approximately 37 weeks for Part I and
for Part II of the study respectively